Abstract
Aberrant expression of microRNAs (miRNAs) has been implicated in various neurological disorders (NDs) of the central nervous system such as Alzheimer disease, Parkinson’s disease, Huntington disease, amyotrophic lateral sclerosis, schizophrenia and autism. If dysregulated miRNAs are identified in patients suffering from NDs, this may serve as a biomarker for the earlier diagnosis and monitoring of disease progression. Identifying the role of miRNAs in normal cellular processes and understanding how dysregulated miRNA expression is responsible for their neurological effects is also critical in the development of new therapeutic strategies for NDs. miRNAs hold great promise from a therapeutic point of view especially if it can be proved that a single miRNA has the ability to influence several target genes, making it possible for the researchers to potentially modify a whole disease phenotype by modulating a single miRNA molecule. Hence, better understanding of the mechanisms by which miRNA play a role in the pathogenesis of NDs may provide novel targets to scientists and researchers for innovative therapies.
Keywords: Alzheimer disease, amyotrophic lateral sclerosis, autism, Huntington disease, microRNA, neurodegeneration, Parkinson’s disease, postmortem brain tissue, schizophrenia.
CNS & Neurological Disorders - Drug Targets
Title:Current Update on Synopsis of miRNA Dysregulation in Neurological Disorders
Volume: 14 Issue: 4
Author(s): Mohammad A. Kamal, Gohar Mushtaq and Nigel H. Greig
Affiliation:
Keywords: Alzheimer disease, amyotrophic lateral sclerosis, autism, Huntington disease, microRNA, neurodegeneration, Parkinson’s disease, postmortem brain tissue, schizophrenia.
Abstract: Aberrant expression of microRNAs (miRNAs) has been implicated in various neurological disorders (NDs) of the central nervous system such as Alzheimer disease, Parkinson’s disease, Huntington disease, amyotrophic lateral sclerosis, schizophrenia and autism. If dysregulated miRNAs are identified in patients suffering from NDs, this may serve as a biomarker for the earlier diagnosis and monitoring of disease progression. Identifying the role of miRNAs in normal cellular processes and understanding how dysregulated miRNA expression is responsible for their neurological effects is also critical in the development of new therapeutic strategies for NDs. miRNAs hold great promise from a therapeutic point of view especially if it can be proved that a single miRNA has the ability to influence several target genes, making it possible for the researchers to potentially modify a whole disease phenotype by modulating a single miRNA molecule. Hence, better understanding of the mechanisms by which miRNA play a role in the pathogenesis of NDs may provide novel targets to scientists and researchers for innovative therapies.
Export Options
About this article
Cite this article as:
Kamal A. Mohammad, Mushtaq Gohar and Greig H. Nigel, Current Update on Synopsis of miRNA Dysregulation in Neurological Disorders, CNS & Neurological Disorders - Drug Targets 2015; 14 (4) . https://dx.doi.org/10.2174/1871527314666150225143637
DOI https://dx.doi.org/10.2174/1871527314666150225143637 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Bridging Over the Troubled Heterogeneity of SPG-Related Pathologies: Mechanisms Unite What Genetics Divide
Current Molecular Medicine Targeting Never-In-Mitosis-A Related Kinase 5 in Cancer: A Review
Current Medicinal Chemistry Novel Therapeutic Strategies for Dementia
CNS & Neurological Disorders - Drug Targets PiWi RNA in Neurodevelopment and Neurodegenerative Disorders
Current Molecular Pharmacology Editorial (Hot Topic: Organic Solute Transporters and Diseases: Potential Therapeutic Targets)
Current Molecular Pharmacology Neuroprotective Strategies for Parkinsons Disease
Current Neuropharmacology W-F Substitutions in Apomyoglobin Increase the Local Flexibility of the N-terminal Region Causing Amyloid Aggregation: A H/D Exchange Study
Protein & Peptide Letters Astrocytes: From the Physiology to the Disease
Current Alzheimer Research X-ray Crystallography and Computational Docking for the Detection and Development of Protein–Ligand Interactions
Current Medicinal Chemistry Inhibitors of Myostatin- and Proteasome-Dependent Signaling for Attenuating Muscle Wasting
Recent Patents on Regenerative Medicine Tracking Stem Cells for Cellular Therapy in Stroke
Current Pharmaceutical Design Trends and Applications of Brain Computer Interfaces
Current Signal Transduction Therapy Exercise-Induced MicroRNA Regulation in the Mice Nervous System is Maintained After Activity Cessation
MicroRNA Mesenchymal Stem Cell Therapy for Acetaminophen-related Liver Injury: A Systematic Review and Meta-analysis of Experimental Studies <i>In Vivo</i>
Current Stem Cell Research & Therapy The Roles of Mesenchymal Stem Cells in Tissue Repair and Disease Modification
Current Stem Cell Research & Therapy Brain Oxidative Stress - Analytical Chemistry and Thermodynamics of Glutathione and NADPH
Current Topics in Medicinal Chemistry Large-Conductance Ca2+-Activated K+ Channels:Physiological Role and Pharmacology
Current Medicinal Chemistry Role of Free Radicals and Poly(ADP-Ribose)Polymerase-1 in the Development of Spinal Cord Injury: New Potential Therapeutic Targets
Current Medicinal Chemistry Glutamate-Mediated Signaling and Autism Spectrum Disorders: Emerging Treatment Targets
Current Pharmaceutical Design Future Therapeutic Directions: New Medications and Insulin Delivery in a Changing World for Effective Diabetes Management
Current Drug Discovery Technologies